This report is not a personal recommendation and does not take into account your personal circumstances or appetite for risk.
| Yesterday’s UK 100 Leaders | Price (p) | % Chg |
| Sage Group | 1,008.5 | 5.3% |
| RELX | 2,603.0 | 5.2% |
| GSK | 1,854.5 | 4.7% |
| Smith & Nephew | 1,048.5 | 4.0% |
| AstraZeneca | 12,154.0 | 3.8% |
| Yesterday’s UK 100 Laggards | Price (p) | % Chg |
| Halma | 3,432.0 | -5.6% |
| Antofagasta | 3,586.0 | -5.4% |
| Weir | 2,600.0 | -4.5% |
| Fresnillo | 2,912.0 | -3.4% |
| Barratt Redrow | 276.2 | -3.3% |
| Major World Indices | Price | % Chg | 1 Year |
| UK 100 INDEX | 10,698 | 0.4% | 15.2% |
| DOW JONES INDUS. AVG | 52,421 | 0.3% | 14.4% |
| DAX INDEX | 25,441 | 0.5% | 7.4% |
| NIKKEI 225 | 63,493 | 0.8% | 41.8% |
| S&P/ASX 200 INDEX | 8,750 | 0.1% | 1.2% |
| Commodity | Units | Price | % Chg |
| WTI Crude Oil (Nymex) | USD/bbl. | 101.39 | 1.34% |
| Brent Crude (ICE) | USD/bbl. | 106.28 | 1.60% |
| Gold Spot | USD/t oz. | 4,300 | 0.0% |
| Copper (Comex) | USd/lb. | 640 | 2.2% |
Click graph to enlarge
The UK 100 is called to open -33 points at at 10,664. Stocks in London are set to open lower on Tuesday, after it was somewhat of an outlier on Monday, when it registered a rise despite artificial intelligence worries hanging over stocks. But European peers are to rise, with the CAC 40 and DAX 40 each called 0.1% higher.
In the US on Monday, Wall Street ended lower, dragged down by AI worries, with the Dow Jones Industrial Average down 0.3%, the S&P 500 down 0.5% and the Nasdaq Composite down 0.6%.
In Tokyo, the Nikkei 225 was down 0.2%. In China, the Shanghai Composite traded 0.3% lower, while the Hang Seng Index in Hong Kong fell 0.7%. The S&P/ASX 200 lost 1.0%. China’s unemployment rate rose in August, with retail sales slowing as industrial production accelerated, official data showed Tuesday.
GSK today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences (Chimagen), a privately held biotechnology company. GSK plans to develop and commercialise the asset for multiple myeloma, with the programme expected to enter phase I trials in 2027.
Kier Group revealed earnings for its full year that Increases, from the same period last year. The company’s earnings totalled £61.7 million, or £0.135 per share. This compares with £56.4 million, or £0.121 per share, last year. Excluding items, Kier Group reported adjusted earnings of £102.3 million or £0.224 per share for the period. The company’s revenue for the period rose 6.7% to £4.352 billion from £4.077 billion last year.
.
UK
Kier Group (KIE) – Full Year Results
MJ Gleeson (GLE) – Full Year Results
US
No noteworthy announcements
UK
Moonpig Group (MOON) – Trading Announcement
Barratt Redrow (BTRW) – Full Year Results
Babcock International (BAB) – Trading Update
US
No noteworthy announcements
UK Average Earnings
UK Claimant Count
UK Employment Change
UK ILO Unemployment Rate
EU ZEW Survey – Economic Sentiment
US ADP Employment Change 4-week average
US NY Empire State Manufacturing Index
UK 100 companies going ex-dividend on 17th September 2026:
None
UK 250 companies going ex-dividend on 17th September 2026:
Foresight Group Holdings
Rank Group
Unite Group
Goodwin
Bridgepoint Group
PPHE Hotel Group
Costain Group
Energean
For any help you may require placing trades or in terms of market information, put a call in to our trading floor – it’s all part of the service.
This research is produced by Accendo Markets Limited. Research produced and disseminated by Accendo Markets is classified as non-independent research, and is therefore a marketing communication. This investment research has not been prepared in accordance with legal requirements designed to promote its independence and it is not subject to the prohibition on dealing ahead of the dissemination of investment research. This research does not constitute a personal recommendation or offer to enter into a transaction or an investment, and is produced and distributed for information purposes only.
Accendo Markets considers opinions and information contained within the research to be valid when published, and gives no warranty as to the investments referred to in this material. The income from the investments referred to may go down as well as up, and investors may realise losses on investments. The past performance of a particular investment is not necessarily a guide to its future performance.